

Digital Synthesis: Homology Modelling and CADD as Pillars of Sustainable Drug Discovery

Dr. Bandi Jyothi¹, Dr. Rajitha Balusani²

¹Associate Professor of Chemistry, Govt. City College Autonomous, Nayapul, Hyderabad, Telangana, India

²Assistant Professor of Chemistry, Govt. City College Autonomous, Nayapul, Hyderabad, Telangana, India

Abstract:

The traditional pharmaceutical discovery process is notoriously resource-intensive, often generating significant chemical waste and consuming vast amounts of energy. This review explores the integration of homology modelling and computer aided drug design (CADD) as transformative "green" methodologies that align with the core principles of sustainability. By utilizing *in silico* protein structure prediction and virtual ligand screening, researchers can avoid the heavy environmental footprint of high-throughput experimental screening. These digital workflows minimize the use of hazardous solvents, reduce "wet-lab" trial-and-error, and optimize atom economy through predictive toxicology (ADMET). Ultimately, the synergy between computational precision and green chemistry provides a road-map for an environmentally responsible pharmaceutical industry that prioritizes waste prevention without compromising therapeutic innovation.

Introduction:

The traditional pharmaceutical pipeline is resource-intensive and often generates significant byproducts. The integration of **Homology Modelling** and **Computer Aided Drug Design (CADD)** serves as a "Green" alternative, aligning with the 12 Principles of Green Chemistry by emphasizing the prevention of waste rather than treating it after creation [1, 2].

The Intersection with Green Chemistry

The synergy between these technologies fulfills several sustainable goals [3] as follows:

- 1. Waste Prevention:** *In silico* methods eliminate the need for physical samples and laboratory facilities, offering a rapid alternative to expensive experimental testing. Historically, drug discovery relied on the synthesis of thousands of analogs to find one lead. By using computational blueprints, we move toward "rational design," where every chemical bond created in a lab is backed by high-confidence digital data. This precision is the ultimate form of waste prevention, as it stops the

creation of "chemical junk"—compounds that would otherwise be synthesized only to be discarded due to poor binding or high toxicity [4].

2. **Atom Economy:** Synthetic methods like multi-component reactions (MCRs) are increasingly adopted to maximize the incorporation of materials into the final product [5].
3. **Safer Solvents:** Computational modeling helps identify greener synthetic pathways, such as aqueous micellar catalysis, which can reduce E-factors (waste-to-product ratios) significantly [6].

Methodology:

1. Homology Modelling: Building the Blueprint

When the experimental 3D structure of a target protein is unknown, homology modelling bridges the gap using known "template" structures [7, 8]. The Process utilizes amino acid sequence similarity to forecast three-dimensional protein structures with unrecognized geometries as follows

1. Sequence retrieval of the target protein -Protein Data Bank (PDB) [9].
2. Selection of a suitable template/s - BLAST) [10, 12]
3. Generation of 3D model - MODELLER [13, 14]
4. Model validation – procheck [15, 16], PROSA [17]

2. CADD: Precision over Persistence

Computational techniques allow for the virtual testing of millions of compounds, prioritizing those with beneficial drug-like characteristics [18]. Identification of active site of the target protein – CASTp [19, 20], Virtual screening [21], and ADME prediction [22] of the generated ligand molecules are the step by step procedures in CADD. In Structure-Based Design (Docking), tools like AutoDock Vina are used to predict the preferred orientation and binding affinity of ligands to receptors. Predictive toxicology identifies bio-accumulative or toxic compounds early in development.

This "fail fast" strategy prevents the chemical waste associated with synthesizing ineffective leads. Below figure 1 depicts the methodology of the homology modelling and virtual screening. Several scientists used the same method for their research work [23-26].




Figure 1: Flow chart depicting the methodology for the lead identification

Discussions:

Homology Modelling and CADD are no longer just supplementary tools; they are the bedrock of modern Green Chemistry [24]. By providing structural data when experimental methods like X-ray crystallography are difficult or expensive, it reduces the need for resource-heavy lab work. Research on Homology Modelling and Drug development highlights its role in speeding up the development process. There is a paradigm shift from "**Trial-and-Error**" to "**Rational Design**"

A critical takeaway is that sustainability in pharmaceuticals is not just an ethical choice but an economic necessity. The reduction in E-factors (the ratio of waste to product) achieved through *in-silico* pre-screening directly translates to lower operational costs. By minimizing the demand for high-purity solvents, specialized waste disposal, and energy-intensive laboratory environments, the "Green" approach facilitated by CADD proves that **environmental stewardship** and **industrial profitability** can coexist.

Homology modelling specifically addresses a major bottleneck: the lack of structural data for many therapeutic targets. By providing reliable 3D models where experimental structures are missing, it democratizes drug discovery for neglected diseases. This ensures that sustainability isn't just about "saving resources" but also about the sustainable distribution of health, allowing for rapid response to new pathogens without the multi-year delay, **addressing the data gap in protein targets** and massive carbon footprint of traditional structural biology.

Ultimately, the future of the field lies in the complete integration of **Artificial Intelligence** with Green Chemistry principles. As computational models become more predictive of real-world biological outcomes, the need for physical "trial" synthesis will continue to shrink. The pharmaceutical industry's

path to **Net Zero** is paved with code. Embracing these computational tools is the only way to ensure that the medicines of tomorrow do not come at the cost of the environment [25-27].

Conclusion

Homology modelling and CADD are essential for environmental stewardship. By replacing the round-bottom flask with high-performance processors, we can discover life-saving medicines without compromising the planet's health. The conclusion of this review synthesizes the shift from traditional, resource-heavy medicinal chemistry to a streamlined, digital-first paradigm. As AI and Machine Learning refine homology models, "in-silico" labs will further minimize the environmental burden of drug discovery. By prioritizing "**Digital First**" approaches, the pharmaceutical industry can achieve sustainable development goals while maintaining therapeutic efficacy

References:

1. Martinengo B, Diamanti E, Uliassi E, Bolognesi ML. Harnessing the 12 Green Chemistry Principles for Sustainable Antiparasitic Drugs: Toward the One Health Approach. *ACS Infect Dis*. 2024 Jun 14;10(6):1856-1870. doi: 10.1021/acsinfecdis.4c00172. Epub 2024 May 9. PMID: 38724015; PMCID: PMC11184551.
2. Evelien Wynendaele, Christophe Furman, Bartosz Wielgomas, Per Larsson, Eelko Hak, Thomas Block, Serge Van Calenbergh, Nicolas Willand, Michal Markuszewski, Luke R. Odell, Gerrit J. Poelarends, Bart De Spiegeleer, Sustainability in drug discovery, *Medicine in Drug Discovery*, Volume 12, 2021, 100107,
3. Stefanache, A.; Marcinschi, A.; Marin, G.-A.; Mitran, A.-M.; Lungu, I.I.; Miftode, A.M.; Crivoi, F.; Lacatusu, D.; Baican, M.; Cioanca, O.; et al. Green Chemistry Approaches in Pharmaceutical Synthesis: Sustainable Methods for Drug Development. *AppliedChem* **2025**, 5,13. <https://doi.org/10.3390/appliedchem5020013>
4. Muhammed, Muhammed Tilahun & Aki, Esin. (2018). Homology modeling in drug discovery: Overview, current applications, and future perspectives. *Chemical Biology & Drug Design*. 93. 12-20. 10.1111/cbdd.13388.
5. Ouma, R.B.O., Ngari, S.M. & Kibet, J.K. A review of the current trends in computational approaches in drug design and metabolism. *Discov Public Health* 21, 108 (2024). <https://doi.org/10.1186/s12982-024-00229-3>
6. Evelien Wynendaele, Christophe Furman, Bartosz Wielgomas, Per Larsson, Eelko Hak, Thomas Block, Serge Van Calenbergh, Nicolas Willand, Michal Markuszewski, Luke R. Odell, Gerrit J. Poelarends, Bart De Spiegeleer, Sustainability in drug discovery, *Medicine in Drug Discovery* Volume 12, 2021, 100107, ISSN 2590-0986, <https://doi.org/10.1016/j.medidd.2021.100107>.
7. Nema, Priyanshu & Purohit, Arpana & Soni, Vandana & Kashaw, Sushil. (2026). A Comprehensive Review on Homology Modelling in Drug Development: Methodologies, Tools, and Evaluation. *Mini-Reviews in Medicinal Chemistry*. 26. 10.2174/0113895575388386251212074901.

8. Venselaar H, Joosten RP, Vroiling B, Baakman CA, Hekkelman ML, Krieger E, Vriend G. Homology modelling and spectroscopy, a never-ending love story. *Eur Biophys J.* 2010 Mar;39(4):551-63. doi: 10.1007/s00249-009-0531-0. Epub 2009 Aug 29. PMID: 19718498; PMCID: PMC2841279.
9. Berman H.M. et al. (2000). The Protein Data Bank. *Nucleic Acids Res*, 28, 235-242.
10. Altschul S.F. et al. (1997). Gapped BLAST and PS-I BLAST: A New Generation of protein Database Search Programs. *Nucleic Acids Res*, 25, 3389-3402.
11. Przybylski D. Rost B. (2008). Powerful Fusion: PSIBLAST and Consensus Sequences. *Bioinformatics*, 24, 1987-1993.
12. Kerfeld C.A. Scott K.M. (2011). Using BLAST to teach "EValueTionary" concepts. *PLoS Biol*, 9, e1001014.
13. Sali A. et al. (1995). Evaluation of Comparative Protein Modeling by MODELLER. *Proteins Struct. Funct. Genet*, 23, 318-326.
14. Webb B. Sali, A. (2014). Comparative Protein Structure Modeling Using MODELLER. *curr. Protoc. Bioinforma*, 47, 5.6.1-5.6.32.
15. Lakshmi B. et al. (2014). Investigations of Ramachandran Disallowed Conformations in Protein Domain Families. *Int. J. Biol. Macromol.*, 63, 119-125.
16. Kleywegt G.J. Jones T.A. (1996). Phi/PsiChology: Ramachandran Revisited *Structure*, 4, 1395-1400.
17. Wiederstein M. Sippl M.J. (2007). ProSAWeb: Interactive Web Service for the Recognition of Errors in Three Dimensional Structures of Proteins. *Nucleic Acids Res*, 35, 407-410.
18. Ugbaja, S.C.; Mushebenge, A.G.-A.; Kumalo, H.; Ngcobo, M.; Gqaleni, N. Potential Benefits of In Silico Methods: A Promising Alternative in Natural Compound's Drug Discovery and Repurposing for HBV Therapy. *Pharmaceutics* **2025**, *18*, 419. <https://doi.org/10.3390/ph18030419>
19. Binkowski T.A. et al. (2003). CASTp: Computed Atlas of Surface Topography of Proteins. *Nucleic Acids Res*, 31, 3352-3355.
20. Dundas J. et al. (2006). CASTp: Computed Atlas of Surface Topography of Proteins with Structural and Topographical Mapping of Functionally Annotated Residues. *Nucleic Acids Res*, 34, 116-118.
21. Geppert H. et al. (2010). Current Trends in Ligand-Based Virtual Screening: Molecular Representations, Data Mining Methods, New Application Areas, and Performance Evaluation. *J. Chem. Inf Model*, 50, 205-216.
22. Ancuceanu R, Lascu BE, Drăgănescu D, Dinu M. In Silico ADME Methods Used in the Evaluation of Natural Products. *Pharmaceutics*. 2025 Jul 31;17(8):1002. doi: 10.3390/pharmaceutics17081002. PMID: 40871023; PMCID: PMC12389637
23. Jyothi Bandi and Navaneetha Nambigari *Asian J. Org. Med. Chem.*, Identification of Novel Anticancer Agent by In silico Methods for Inhibition of KLK-12 Protein., 2021, 6(1), 13-23. DOI: 10.14233/ajomc.2021.AJOMC-P30
24. Bandi, J., Malkhed, V., & Nambigari, N. (2022). An insilico study of KLK-14 protein and its inhibition with curcumin and its derivatives. *Chemical Papers*, 1-12. <https://doi.org/10.1007/s11696-022-02209-w>

25. Jyothi Bandi Navaneetha Nambigari, *Novel Aspects on Chemistry and Biochemistry* international Book,, An In-silico Study of Pathological Angiogenesis; Design of Anticancer Agent Inhibiting KKK – 12, , 12 January 2024, Vol. 9, 30-46. <https://doi.org/10.9734/bpi/nacb/v9/7538A>
26. Bandi Jyothi and Navaneetha Nambigari, futuristic trends in Chemical Material Sciences & Nano Technology, Kallikrein related peptidases as angiogenic targets for breast and prostate cancer, , Volume 3 Book 1, 431-440, e-ISBN: 978-93-5747-867-0